Tyra Biosciences, Inc.

What they do

Tyra Biosciences is developing oral small molecule precision medicines using its in-house SN P platform, focusing on Fibroblast Growth Factor Receptor (FGFR) biology. Its lead candidate, oral dabogratinib (FGFR3-selective), is being studied in three Phase 2 trials: SURF303 for low-grade upper tract urothelial carcinoma (LG-UTUC), SURF302 for intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), and BEACH301 for achondroplasia (ACH) in children. The company has no approved products or commercial revenue.

Revenue drivers

• Oral dabogratinib – SURF303 (LG-UTUC) — Phase 2a/b pivotal-intent study for low-grade upper tract urothelial carcinoma, a rare cancer where ~85% of tumors are FGFR3-driven. Initial results expected 2027; no revenue yet.
• Oral dabogratinib – SURF302 (IR NMIBC) — Phase 2 study for FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer. Initial data expected September 2026; no revenue yet.
• Oral dabogratinib – BEACH301 (Achondroplasia) — Phase 2 dose-escalation/expansion study in children ages 3–10. Safety sentinel cohort cleared 4 dose levels; a fifth dose level (0.625 mg/kg) opened. Initial results expected end of Q1 2027; no revenue yet.

Recent performance

For the second quarter ended June 30, 2026, Tyra reported a net loss of $119.9 million for fiscal year 2025 (diluted EPS -$2.01) and $86.5 million for fiscal 2024 (-$1.51). Operating cash flow was -$95.1 million in 2025 and -$69.8 million in 2024. Cash, cash equivalents and marketable securities stood at $353.9 million as of June 30, 2026, providing a runway into the second half of 2028. The company remains pre-revenue with no approved products.

Strategy

Tyra is executing a 'dabogratinib 3x3' strategy: develop the first orally available, FGFR3-selective inhibitor in three potentially pivotal clinical studies for three blockbuster indications: LG-UTUC, IR NMIBC, and achondroplasia. The company leverages its SN P platform for rapid molecular design and has appointed Jonathan Day as EVP of Clinical Development to strengthen skeletal dysplasia efforts. Management prioritizes data readouts from SURF302 in September 2026 and BEACH301 in early 2027 to advance regulatory submissions.

Risks

• Clinical trial failure — All product candidates are in Phase 2; negative or uncompetitive data from SURF302, SURF303, or BEACH301 could materially impair the pipeline and company value.
• Regulatory and approval uncertainty — No FDA approvals to date; delays or rejections in pivotal trials or NDA submissions would prevent commercialization and require additional financing.
• Cash burn and dilution — Annual net losses increased from -$69.1M (2023) to -$119.9M (2025); despite $353.9M cash, operating losses may require future equity or debt financing, diluting shareholders.
• Competitive landscape — First-generation FGFR inhibitors and other targeted therapies (e.g., for NMIBC, achondroplasia) may limit dabogratinib’s market opportunity even if approved.

Outlook

Management expects initial Phase 2 data from the SURF302 IR NMIBC study in September 2026, including safety from >40 patients and efficacy from >20 patients at two dose levels. Initial safety sentinel cohort results from BEACH301 (ACH), comprising ~25 children across 5 dose levels with 6-month annualized height velocity, are now anticipated by the end of Q1 2027. SURF303 LG-UTUC initial results are guided for 2027. The company projects cash runway into the second half of 2028.